Overview

* Immunic ( IMUX ) Q2 net loss $27 mln, with increased R&D expenses

* Cash and Cash Equivalents as of June 30, 2025 were $55.3 million.

Outlook

* Immunic ( IMUX ) does not have adequate liquidity to fund its operations for at least twelve months from June 30, 2025

Result Drivers

* FINANCIAL STRENGTH - Raised $70.1 mln through two financings

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$26.82

Income mln

Q2 Basic -$0.2

EPS

Q2 -$27.08

Income mln

From

Operatio

ns

Q2 $27.08

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Immunic Inc ( IMUX ) is $10.00, about 90.2% above its August 6 closing price of $0.98

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)